Solid Tumor Malignancy Clinical Trial
Official title:
An Investigator Sponsored Phase I/II Study of Selinexor in Combination With Irinotecan in Adults With Solid Tumors
The purpose of this study is to determine the safety, tolerability and maximum tolerated dose of selinexor (KPT-330) in combination with Irinotecan in patients with solid tumors. A secondary purpose is to evaluate the pharmacokinetics (PK) of selinexor with irinotecan.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03822117 -
Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
|
Phase 2 | |
| Recruiting |
NCT05768269 -
A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
|
||
| Completed |
NCT00647764 -
Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas
|
Phase 1 | |
| Recruiting |
NCT05164016 -
Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients
|
||
| Completed |
NCT04847050 -
A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy, Including Boost...
|
Phase 2 |